India's Pharma Sector Undergoes Major Ethics Overhaul with New Marketing Code

India's pharmaceutical industry is now operating under significantly tougher ethical guidelines as the government's Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, which became mandatory, tightens its grip on how drugs are promoted. This revamped code, announced by Minister of State for Chemicals and Fertilizers Anupriya Patel in the Lok Sabha, mandates that all Pharmaceutical Companies establish internal Ethics Committees for Pharmaceutical Marketing Practices (ECPMPs) and appoint dedicated Ethics Officers to oversee compliance. The new rules also introduce a robust Complaint Redressal Mechanism and require annual Marketing Expenditure Disclosure, marking a clear shift towards greater transparency and accountability across the sector. The UCPMP 2024, first notified in March 2024 and further amended in September 2025, replaces a largely voluntary 2015 version, directly addressing concerns about Unethical Marketing Practices like providing gifts or hospitality to Healthcare Professionals (HCPs) and their families. This move by the Department of Pharmaceuticals (DoP) aims to ensure that promotional activities are responsible and patient-centric, regulating the interactions between drug manufacturers and medical practitioners to prevent undue influence. The code builds on existing frameworks like the Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002, by adding specific industry-side enforcement and disclosure requirements. Going forward, Pharmaceutical Companies will face independent audits and must submit annual Self-declarations of compliance, with a two-layer adjudication process that includes an Apex Committee for Pharma Marketing Practices (ACPMP) at the Department of Pharmaceuticals for appeals. While industry players have largely adopted a pragmatic approach, some concerns remain regarding the cost of compliance for smaller firms and the balance between self-regulation by industry associations versus stronger statutory backing. The implementation of these new norms will be closely watched as India pushes to align its pharma marketing with global ethical standards.